{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:24:51Z","timestamp":1787063091260,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"DOI":"10.7759\/cureus.114731","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:28:11Z","timestamp":1787059691000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular and Mortality Outcomes in Lean Versus Non-lean Steatotic Liver Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Husam","family":"Jawarneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Yong","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad F","family":"Alnoimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanad","family":"Syam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel A","family":"Irshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Alqadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad R","family":"Falahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noorhan  M","family":"Al-Kadhimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath A","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader O","family":"Rababah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Alrababah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020, 73:202-9. 10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher G","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020, 69:1691-705. 10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye Q","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al.. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020, 5:739-52. 10.1016\/S2468-1253(20)30077-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2016.00068","article-title":"Non-alcoholic fatty liver disease in lean subjects: characteristics and implications","volume":"5","author":"Kumar R","year":"2017","unstructured":"Kumar R, Mohan S. Non-alcoholic fatty liver disease in lean subjects: characteristics and implications. J Clin Transl Hepatol. 2017, 5:216-23. 10.14218\/JCTH.2016.00068","journal-title":"J Clin Transl Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08764-4","article-title":"Mortality, hepatic decompensation, and cardiovascular outcomes in lean vs. non-lean MASLD cirrhosis: a Veterans Affairs cohort study","volume":"70","author":"Njei B","year":"2025","unstructured":"Njei B, Mezzacappa C, John BV, et al.. Mortality, hepatic decompensation, and cardiovascular outcomes in lean vs. non-lean MASLD cirrhosis: a Veterans Affairs cohort study. Dig Dis Sci. 2025, 70:802-13. 10.1007\/s10620-024-08764-4","journal-title":"Dig Dis Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.17015","article-title":"Increased mortality among lean versus non-lean adults with MASLD: a multicenter study","volume":"40","author":"Ghani L","year":"2025","unstructured":"Ghani L, Aboona MB, Faulkner CS, et al.. Increased mortality among lean versus non-lean adults with MASLD: a multicenter study. J Gastroenterol Hepatol. 2025, 40:1919-25. 10.1111\/jgh.17015","journal-title":"J Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.016","article-title":"Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study","volume":"20","author":"Ahmed OT","year":"2022","unstructured":"Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study. Clin Gastroenterol Hepatol. 2022, 20:1374-81. 10.1016\/j.cgh.2021.07.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17424","article-title":"Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities","volume":"57","author":"Wijarnpreecha K","year":"2023","unstructured":"Wijarnpreecha K, Li F, Lundin SK, et al.. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023, 57:1014-27. 10.1111\/apt.17424","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02784-3","article-title":"Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease","volume":"25","author":"Zhang Z","year":"2026","unstructured":"Zhang Z, Lu J, Chen M, et al.. Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease. Lipids Health Dis. 2026, 25:6. 10.1186\/s12944-025-02784-3","journal-title":"Lipids Health Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000974","article-title":"Increased cardiovascular and cerebrovascular events in patients with lean vs non-lean MASLD: a multicenter analysis","volume":"17","author":"Al Ta\u2019ani O","year":"2026","unstructured":"Al Ta\u2019ani O, Alhalalmeh Y, Alabdallat M, et al.. Increased cardiovascular and cerebrovascular events in patients with lean vs non-lean MASLD: a multicenter analysis. Clin Transl Gastroenterol. 2026, 17:e00974. 10.14309\/ctg.0000000000000974","journal-title":"Clin Transl Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10716-z","article-title":"Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals","volume":"18","author":"Souza M","year":"2024","unstructured":"Souza M, Diaz I, Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int. 2024, 18:1396-415. 10.1007\/s12072-024-10716-z","journal-title":"Hepatol Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.41.6.12044","article-title":"Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Miao P","year":"2025","unstructured":"Miao P, Shao Z, Jiang J. Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Pak J Med Sci. 2025, 41:1845-53. 10.12669\/pjms.41.6.12044","journal-title":"Pak J Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.17605\/OSF.IO\/F8XRZ","article-title":"Cardiovascular outcomes in lean versus non-lean metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","author":"Jawarneh H","year":"2026","unstructured":"Jawarneh H, Goh ZY, Alnoimat MF, et al.. Cardiovascular outcomes in lean versus non-lean metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Open Sci Framework. 2026, 10.17605\/OSF.IO\/F8XRZ","journal-title":"Open Sci Framework"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JAC","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02848-7","article-title":"Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease","volume":"23","author":"Ishido S","year":"2023","unstructured":"Ishido S, Tamaki N, Takahashi Y, et al.. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. BMC Gastroenterol. 2023, 23:211. 10.1186\/s12876-023-02848-7","journal-title":"BMC Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.066","article-title":"Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases","volume":"19","author":"Weinberg EM","year":"2021","unstructured":"Weinberg EM, Trinh HN, Firpi RJ, et al.. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clin Gastroenterol Hepatol. 2021, 19:996-1008. 10.1016\/j.cgh.2020.06.066","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/20406223251378867","article-title":"The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study","volume":"16","author":"Dou Y","year":"2025","unstructured":"Dou Y, Cui J, Gu Q, et al.. The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study. Ther Adv Chronic Dis. 2025, 16:20406223251378867. 10.1177\/20406223251378867","journal-title":"Ther Adv Chronic Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16049","article-title":"Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature","volume":"38","author":"Almomani A","year":"2023","unstructured":"Almomani A, Kumar P, Onwuzo S, et al.. Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature. J Gastroenterol Hepatol. 2023, 38:269-73. 10.1111\/jgh.16049","journal-title":"J Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab339","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality","volume":"106","author":"Semmler G","year":"2021","unstructured":"Semmler G, Wernly S, Bachmayer S, et al.. Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality. J Clin Endocrinol Metab. 2021, 106:2670-7. 10.1210\/clinem\/dgab339","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/postmj\/qgad035","article-title":"Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease","volume":"99","author":"Biswas S","year":"2023","unstructured":"Biswas S, Vaishnav M, Farooqui N, et al.. Impact of body mass index on disease progression and outcomes in patients with nonalcoholic fatty liver disease. Postgrad Med J. 2023, 99:1094-103. 10.1093\/postmj\/qgad035","journal-title":"Postgrad Med J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-025-00378-w","article-title":"NPR is an independent risk factor for predicting all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2007-2020","volume":"23","author":"Ye D","year":"2025","unstructured":"Ye D, Ji X, Ma Y, et al.. NPR is an independent risk factor for predicting all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2007-2020. Popul Health Metr. 2025, 23:15. 10.1186\/s12963-025-00378-w","journal-title":"Popul Health Metr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01509-3","article-title":"Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease","volume":"20","author":"Iritani S","year":"2020","unstructured":"Iritani S, Akuta N, Kawamura Y, et al.. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol. 2020, 20:368. 10.1186\/s12876-020-01509-3","journal-title":"BMC Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.04.045","article-title":"Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity","volume":"15","author":"Fracanzani AL","year":"2017","unstructured":"Fracanzani AL, Petta S, Lombardi R, et al.. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017, 15:1604-11. 10.1016\/j.cgh.2017.04.045","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-3622","article-title":"Liver-related mortality is increased in lean subjects with non-alcoholic fatty liver disease compared to overweight and obese subjects","volume":"30","author":"Feldman A","year":"2021","unstructured":"Feldman A, Wernly B, Strebinger G, et al.. Liver-related mortality is increased in lean subjects with non-alcoholic fatty liver disease compared to overweight and obese subjects. J Gastrointestin Liver Dis. 2021, 30:366-73. 10.15403\/jgld-3622","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou B","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020, 288:139-51. 10.1111\/joim.13069","journal-title":"J Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63453-6","article-title":"Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study","volume":"14","author":"Charatcharoenwitthaya P","year":"2024","unstructured":"Charatcharoenwitthaya P, Karaketklang K, Aekplakorn W. Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study. Sci Rep. 2024, 14:12663. 10.1038\/s41598-024-63453-6","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000471","article-title":"Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Behari J","year":"2024","unstructured":"Behari J, Wang R, Luu HN, McKenzie D, Molinari M, Yuan JM. Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2024, 8:0471. 10.1097\/HC9.0000000000000471","journal-title":"Hepatol Commun"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01976-6","article-title":"Differential DNAm-GDF15 and mitochondrial profile in lean MAFLD","volume":"26","author":"Alarabi M","year":"2026","unstructured":"Alarabi M, Pan Z, George J, Eslam M. Differential DNAm-GDF15 and mitochondrial profile in lean MAFLD. Clin Exp Med. 2026, 26:199. 10.1007\/s10238-025-01976-6","journal-title":"Clin Exp Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61896-5","article-title":"Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals","volume":"14","author":"Zhang P","year":"2024","unstructured":"Zhang P, Zeng Y, Yang S, et al.. Mortality outcomes in diabetic metabolic dysfunction-associated fatty liver disease: non-obese versus obese individuals. Sci Rep. 2024, 14:11320. 10.1038\/s41598-024-61896-5","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100097","article-title":"The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: a longitudinal study","volume":"4","author":"Aneni EC","year":"2020","unstructured":"Aneni EC, Bittencourt MS, Teng C, et al.. The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: a longitudinal study. Am J Prev Cardiol. 2020, 4:100097. 10.1016\/j.ajpc.2020.100097","journal-title":"Am J Prev Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.11.002","article-title":"Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: a long-term prospective cohort study","volume":"57","author":"Zhang Q","year":"2025","unstructured":"Zhang Q, Wang Y, Liu S, Zhu S, Li P, Wu S. Mortality risk associated with MASLD, MASLD type and different cardiometabolic risk factors in IBD patients: a long-term prospective cohort study. Dig Liver Dis. 2025, 57:744-52. 10.1016\/j.dld.2024.11.002","journal-title":"Dig Liver Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02373-1","article-title":"Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China","volume":"30","author":"Zhu R","year":"2025","unstructured":"Zhu R, Xu C, Jiang S, et al.. Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a health check-up population in China. Eur J Med Res. 2025, 30:137. 10.1186\/s40001-025-02373-1","journal-title":"Eur J Med Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15880","article-title":"Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study","volume":"44","author":"Aboona MB","year":"2024","unstructured":"Aboona MB, Faulkner C, Rangan P, et al.. Disparities among ethnic groups in mortality and outcomes among adults with MASLD: a multicenter study. Liver Int. 2024, 44:1316-28. 10.1111\/liv.15880","journal-title":"Liver Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006712","article-title":"Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study","volume":"96","author":"Hashimoto Y","year":"2017","unstructured":"Hashimoto Y, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study. Medicine (Baltimore. 2017, 96:e6712. 10.1097\/MD.0000000000006712","journal-title":"Medicine (Baltimore"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities","volume":"4","author":"Golabi P","year":"2020","unstructured":"Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD according to the body composition and presence of metabolic abnormalities. Hepatol Commun. 2020, 4:1136-48. 10.1002\/hep4.1534","journal-title":"Hepatol Commun"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2081","article-title":"Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China","volume":"6","author":"Lan Y","year":"2022","unstructured":"Lan Y, Lu Y, Li J, et al.. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: a cohort study in China. Hepatol Commun. 2022, 6:3393-405. 10.1002\/hep4.2081","journal-title":"Hepatol Commun"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13351","article-title":"Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease","volume":"14","author":"Choi KY","year":"2023","unstructured":"Choi KY, Kim TY, Chon YE, et al.. Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2023, 14:2747-56. 10.1002\/jcsm.13351","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02716-3","article-title":"Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease","volume":"21","author":"Chung GE","year":"2023","unstructured":"Chung GE, Yu SJ, Yoo JJ, et al.. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. BMC Med. 2023, 21:4. 10.1186\/s12916-022-02716-3","journal-title":"BMC Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00154","article-title":"Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese health examination populations","volume":"11","author":"Xu X","year":"2023","unstructured":"Xu X, Zhou X, Tian T, et al.. Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese health examination populations. J Clin Transl Hepatol. 2023, 11:777-86. 10.14218\/JCTH.2022.00154","journal-title":"J Clin Transl Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/livers5040058","article-title":"From \u201cMAFLD\u201d to \u201cMASLD\u201d: Was this revolution worth it? A head-to-head comparison of MAFLD and MASLD criteria in estimating liver disease progression and cardiovascular risk in real life","volume":"5","author":"Dallio M","year":"2025","unstructured":"Dallio M, Romeo M, Di Nardo F, et al.. From \u201cMAFLD\u201d to \u201cMASLD\u201d: Was this revolution worth it? A head-to-head comparison of MAFLD and MASLD criteria in estimating liver disease progression and cardiovascular risk in real life. Livers. 2025, 5:58. 10.3390\/livers5040058","journal-title":"Livers"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.117893","article-title":"Associations of MAFLD subtypes and air pollutants with multi-system morbidity and all-cause mortality: a prospective cohort study","volume":"291","author":"Zhang J","year":"2025","unstructured":"Zhang J, Ran S, Wei S, et al.. Associations of MAFLD subtypes and air pollutants with multi-system morbidity and all-cause mortality: a prospective cohort study. Ecotoxicol Environ Saf. 2025, 291:117893. 10.1016\/j.ecoenv.2025.117893","journal-title":"Ecotoxicol Environ Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521575-cardiovascular-and-mortality-outcomes-in-lean-versus-non-lean-steatotic-liver-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:28:13Z","timestamp":1787059693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521575-cardiovascular-and-mortality-outcomes-in-lean-versus-non-lean-steatotic-liver-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.114731","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}